Morning Market Brief: Breakthrough Biology Meets Scalable Platforms as Innovators Surge into Focus

Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib , its next-generation oral TYK2 inhibitor, in ...

Dark Blue Therapeutics acquired by Amgen for up to $840 million

Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myeloid Leukemia Acquisition brings ...

Alvotech announces planned CEO succession and leadership transition

R- bert Wessman to continue serving as Executive Chairman in full-time capacityLisa Graver appointed Chief Executive Officer REYKJAVIK, ICELAND (January 6, 2026) - Alvotech (NASDAQ: ALVO), a global ...